Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Karyotyping01:17

Karyotyping

70.8K
Overview
70.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.3K
Histone Variants at the Centromere02:30

Histone Variants at the Centromere

5.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
5.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of gene variant type and location with breast cancer risk in the general population.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Aromatase expression in atypical ductal hyperplasia in women.

Breast cancer research and treatment·2017
Same author

Second primary malignancies in multiple myeloma: an overview and IMWG consensus.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

A Tumor Growth Inhibition Model Based on M-Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single-Agent Carfilzomib Use.

CPT: pharmacometrics & systems pharmacology·2016
Same author

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.

Blood cancer journal·2015
Same journal

Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.

Blood cancer journal·2026
Same journal

Effect of anemia developed after ruxolitinib initiation on adverse outcomes in patients with myelofibrosis: a nationwide cohort study.

Blood cancer journal·2026
Same journal

Dynamics of IDH1/2 mutated clones in acute myeloid leukemia challenge their use as universal MRD markers.

Blood cancer journal·2026
Same journal

Circulating CD20-positive extracellular vesicles impair rituximab efficacy and predict outcomes in diffuse large B-cell lymphoma.

Blood cancer journal·2026
Same journal

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same journal

Baseline plasma-informed circulating tumor DNA analyses comparing multiplex digital PCR and NGS for longitudinal monitoring in Hodgkin lymphoma.

Blood cancer journal·2026
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.

A J Greenberg1, S Philip2, A Paner3

  • 1Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, MN, USA.

Blood Cancer Journal
|January 3, 2015
PubMed
Summary
This summary is machine-generated.

Black patients with multiple myeloma (MM) show different cytogenetic profiles compared to white patients. These differences in genetic abnormalities, including immunoglobulin heavy chain (IgH) translocations and chromosomal deletions, are significant in MM subtypes.

More Related Videos

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.6K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.6K

Related Experiment Videos

Last Updated: Apr 19, 2026

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma
07:53

Interphase Fluorescence in situ Hybridization of Bone Marrow Smears of Multiple Myeloma

Published on: April 15, 2022

4.9K
Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

84.6K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.6K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Multiple myeloma (MM) is a hematologic malignancy with diverse cytogenetic subtypes.
  • Understanding these subtypes is crucial for prognosis and treatment strategies.
  • Previous studies have characterized MM cytogenetics primarily in Caucasian populations.

Purpose of the Study:

  • To investigate and compare the prevalence of specific cytogenetic abnormalities in Black patients with newly diagnosed multiple myeloma (MM).
  • To compare these findings with a well-characterized Caucasian cohort from the Mayo Clinic.
  • To identify potential differences in MM subtypes between racial groups.

Main Methods:

  • Retrospective analysis of cytogenetic data from 292 Black patients with newly diagnosed MM.
  • Fluorescent in situ hybridization (FISH) testing results were utilized.
  • Comparison of prevalence rates of four key cytogenetic abnormalities (t(11;14), t(4;14), monosomy 13/del13q, monosomy 17/del17p) with a cohort of 471 Caucasian MM patients.

Main Results:

  • Significant differences in the prevalence of t(11;14) immunoglobulin heavy chain (IgH) translocation between Black (6.5%) and White (17.6%) patients (P<0.0001).
  • Black patients exhibited lower rates of t(4;14) IgH translocation (5.5% vs 10%), monosomy 13/del13q (29.1% vs 49.3%), and monosomy 17/del17p (7.9% vs 13%).
  • A higher proportion of Black patients (63.4%) lacked these four specific abnormalities compared to White patients (34.6%) (P<0.001).

Conclusions:

  • There are significant disparities in the cytogenetic landscape of multiple myeloma between Black and White populations.
  • The observed differences suggest that MM in Black individuals may be associated with alternative genetic alterations, potentially including hyperdiploid MM or other IgH translocations.
  • Further research is warranted to elucidate the full spectrum of MM cytogenetics in diverse populations and its clinical implications.